PPARA and metabolic dysfunction-associated steatotic liver disease: Elafibranor, the PPARα/δ dual agonist developed by Genfit (Loos, France), has been abandoned at the phase 3 clinical trial against NAFLD/NASH due to its non-significant effect on the primary endpoint of the resolution of NASH without a worsening of fibrosis [10].